The list of new medicines recommended for approval at the October meeting of the EMA's human medicines committee includes Brinsupri, the first treatment for serious chronic lung disease non-cystic ...

"GMA" and sponsor Insmed explore life with a rare chronic condition that affects around 500,000 Americans, leaving them unable to do the things they love. Maddow Blog | Why the North Carolina GOP ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...

(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help prevent ...

Exclusive collaboration to deliver AI-driven solutions for predictive maintenance, engineering insights, and enhanced customer experience. ORLANDO, Fla., Sept. 17, 2025 /PRNewswire/ -- Osmosis, a ...

Reverse osmosis (RO) is a vital water purification technology used in various applications such as boiler feedwater treatment, cooling water systems, and wastewater recycling. The feedwater for RO can ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

The FDA has approved brensocatib tablets in 10-mg and 25-mg doses as once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children aged 12 years or older, according to a ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...